

The Role of Immunotherapy in the Treatment of Lung Cancer: Current Status and Future Directions

Charles Boshoff*

Department of Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Introduction

Lung cancer is a significant health problem, and it remains one of the leading causes of cancer-related deaths worldwide. Despite advances in traditional chemotherapy and radiation therapy, the five-year survival rate for lung cancer remains low. Therefore, there is an urgent need to develop more effective treatment options for this devastating disease.

In recent years, immunotherapy has emerged as a promising treatment option for patients with lung cancer. This innovative approach harnesses the power of the body's immune system to fight cancer, providing potential benefits over traditional chemotherapy and radiation therapy. Immunotherapy has shown impressive results in clinical trials, including improved survival rates and fewer side effects [1].

Description

Immunotherapy is an innovative approach to treating lung cancer that involves harnessing the body's immune system to fight cancer cells. This approach differs from traditional chemotherapy and radiation therapy, which aim to directly destroy cancer cells. Immunotherapy uses drugs that activate the immune system to recognize and attack cancer cells. There are different types of immunotherapy drugs used in the treatment of lung cancer, including immune checkpoint inhibitors, CAR T-cell therapy, and therapeutic vaccines. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs in lung cancer treatment. They work by blocking proteins that inhibit the immune system's ability to recognize and attack cancer cells. Clinical trials have shown that immunotherapy can be an effective treatment option for lung cancer, particularly in patients with advanced or metastatic disease. Immunotherapy has been shown to improve overall survival rates and to cause fewer side effects than traditional chemotherapy and radiation therapy [2].

However, not all lung cancer patients are suitable candidates for immunotherapy, and some patients may not respond to these treatments. Additionally, immunotherapy drugs can have side effects, including fatigue, skin rash, and inflammation of the lungs or other organs. Despite these challenges, immunotherapy represents a significant advancement in the treatment of lung cancer, and ongoing research is focused on developing new immunotherapy drugs and combinations of drugs that can improve outcomes for lung cancer patients [3].

The current status of immunotherapy in the treatment of lung cancer is rapidly evolving, and several immune checkpoint inhibitors have been

approved by the FDA for the treatment of lung cancer, including nivolumab, pembrolizumab, and atezolizumab. These drugs have shown significant improvements in survival rates in lung cancer patients, particularly in those with advanced or metastatic disease. However, the efficacy of immunotherapy drugs can vary depending on the specific subtype of lung cancer, and identifying patients who are most likely to benefit from these treatments can be challenging. Research is ongoing to develop biomarkers that can predict which patients will respond best to immunotherapy [4].

In addition to identifying predictive biomarkers, future directions for immunotherapy in the treatment of lung cancer include developing combination therapies that can enhance the immune system's ability to attack cancer cells. This could involve combining immunotherapy with other types of cancer treatments, such as chemotherapy, radiation therapy, or targeted therapy. Personalized medicine approaches are also being developed, which involve tailoring immunotherapy treatments to individual patients based on the specific characteristics of their cancer. This could involve analyzing the genetic mutations of the tumor, the patient's immune system profile, and other factors to develop a personalized treatment plan. Overall, the future of immunotherapy in the treatment of lung cancer is promising, and ongoing research is focused on developing new drugs and combination therapies that can improve outcomes for patients. As the field continues to evolve, it is likely that immunotherapy will become an increasingly important treatment option for lung cancer patients [5].

Conclusion

Immunotherapy represents a significant advancement in the treatment of lung cancer, offering a more targeted and effective treatment option for patients. The current status of immunotherapy in lung cancer treatment is promising, with several drugs approved by the FDA and ongoing research aimed at improving outcomes for patients. However, challenges remain, including the need to identify predictive biomarkers to identify patients who are most likely to benefit from immunotherapy, and the need for further research to develop effective combination therapies and personalized treatment approaches. Despite these challenges, the potential benefits of immunotherapy for lung cancer patients are significant, including improved survival rates and fewer side effects than traditional chemotherapy and radiation therapy. As research in this field continues, it is likely that immunotherapy will become an increasingly important part of the lung cancer treatment landscape, offering new hope for patients and their families.

References

1. Herbst RS, Morgensztern D, Boshoff C. The Biology and Management of Non-Small Cell Lung Cancer. *Nature* 553 (2018): 446-54.
2. Brahmer, Julie R., Charles G. Drake, Ira Wollner and Elizabeth Stankevich, et al. "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates." *J clin oncol* 28 (2010): 3167.
3. Gandhi, L., D. Rodriguez-Abreu, S. Gadgeel and M. Domine, et al. "Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell." *Lung Cancer N Engl J Med* 378 (2018): 2078.
4. Horn, Leora, David R. Spigel, Everett E. Vokes and Elena Poddubskaya, et al. "Nivolumab versus docetaxel in previously treated patients with advanced non-

*Address for Correspondence: Charles Boshoff, Department of Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; E-mail: Cboshoff36@gmail.com

Copyright: © 2023 Boshoff C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 31 December, 2022, Manuscript No. LDT-23-95197; Editor Assigned: 03 January, 2023, PreQC No. P-95197; Reviewed: 07 March, 2023, QC No. Q-95197; Revised: 13 March, 2023, Manuscript No. R-95197; Published: 21 March 2023, DOI: 10.37421/2472-1018.2023.9.176

- small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)." *J Clin Oncol* 35 (2017): 3924.
5. Hellmann, Matthew D., Naiyer A. Rizvi, Jonathan W. Goldman and Neal E. Ready, et al. "Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study." *Lancet Oncol* 18 (2017): 31-41.

How to cite this article: Boshoff, Charles. "The Role of Immunotherapy in the Treatment of Lung Cancer: Current Status and Future Directions." *J Lung Dis Treat* 9 (2023): 176.